Kaneka Corporation (FRA:KKA)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.81B +22.4% |
| Revenue (ttm) | 4.43B +0.6% |
| Net Income | 168.97M +22.4% |
| EPS | 2.72 +25.0% |
| Shares Out | n/a |
| PE Ratio | 10.71 |
| Forward PE | n/a |
| Dividend | 0.89 (3.01%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | n/a |
| Open | 30.00 |
| Previous Close | 30.20 |
| Day's Range | 29.60 - 30.00 |
| 52-Week Range | 21.40 - 31.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Kaneka
Kaneka Corporation engages in the manufacture and sale of polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan and internationally. It provides impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, and biodegradable polymer, as well as engineering resin for injection molding, acrylic film, and isobutylene-based thermoplastic elastomer produ... [Read more]
Financial Performance
In fiscal year 2026, Kaneka's revenue was 811.64 billion, an increase of 0.55% compared to the previous year's 807.20 billion. Earnings were 30.98 billion, an increase of 22.40%.
Financial numbers in JPY Financial StatementsNews
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kaneka Medical America LLC , a subsidiary company of Kaneka Corporation , innovating embolization coil technology for neurovascular therapies, today announc...